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Unfortunately, there was a typographic error in this article. The sentence that read:
“The results of our trial are broadly similar with those reported for other LAMA+LAMA FDCs [24–26].”
should have read as follows:
“The results of our trial are broadly similar with those reported for other LAMA+LABA FDCs [24–26].”
The online version of the article has been amended to reflect this correction.
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Figure 5 from the above mentioned article was published with an error: the element at the top centre
should depict a decrease in GSNO (S-nitrosoglutathione), not a decrease in GSNO reductase. The
corrected version of the figure is reproduced below, and the online version of the article has been
amended to reflect this correction.
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FIGURE 5 Proposed scheme showing the effect of increased S-nitrosoglutathione reductase (GSNOR) on asthma.
A subset of patients, as previously reported [10, 14−16], has a diathesis to increased GSNOR expression. This is driven
by allergic airway inflammation. In turn, this causes a decrease in airway GSNO levels that leads to smooth muscle
constriction [1−7, 32−34] and a further increase in T-helper cell (Th)2 cytokine expression [5].
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